Clinical Trial: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Relapsed/Refractory B-Cell Lymphoma
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma
Brief Summary:
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL).The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Read more